SUNNYVALE, Calif., May 23, 2023 (GLOBE NEWSWIRE) — BioCardia®, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases today announced that the next Data Safety Monitoring Board (DSMB) meeting for the CardiAMP Cell Therapy Trial for Heart Failure is scheduled to take place […]
Author: Ken Dropiewski
Arrowhead Presents Interim Data from ARO-ANG3 Phase 2 GATEWAY Study in Patients with HoFH
– 44-48% Mean Reductions in LDL-C Achieved on Top of Continued Standard of Care – Phase 3 Planning is Ongoing PASADENA, Calif.–(BUSINESS WIRE)–Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today presented interim data from the ongoing Phase 2 GATEWAY clinical study of ARO-ANG3, the company’s investigational RNAi therapeutic designed to reduce expression […]
CORVIA MEDICAL RELEASES TWO-YEAR CLINICAL TRIAL RESULTS CONFIRMING SUSTAINED BENEFIT AND SAFETY OF ITS ATRIAL SHUNT IN HEART FAILURE PATIENTS
FIRST-EVER PHASE III RANDOMIZED CONTROLLED TRIAL OF ATRIAL SHUNT THERAPY SHOWS CONTINUED PROMISE TEWKSBURY, Mass., May 22, 2023 /PRNewswire/ — Corvia Medical, Inc, a company dedicated to transforming the treatment of heart failure, today announced two-year results from its REDUCE LAP-HF II randomized clinical trial confirming safety and sustained efficacy of the […]
Abbott Unveils Late-Breaking Data Showing the World’s First Dual-Chamber Leadless Pacemaker Study Met All Three Primary Endpoints
Abbott’s AVEIR™ DR i2i™ IDE study is the industry’s first prospective study on the safety and performance of the world’s first dual-chamber leadless pacemaker The study successfully met all three of its primary safety and performance endpoints Abbott’s investigational AVEIR DR leadless pacemakers have been submitted for evaluation by the […]
New Data From iRhythm Reinforce the Utility of Long-Term Ambulatory Cardiac Monitoring for Increased Diagnostic Yield and Improved Diagnostic Accuracy of Actionable Arrhythmias
Clinical studies presented at Heart Rhythm 2023 build on the totality of clinical evidence that continue to highlight the value of iRhythm’s Zio products and services across a wide range of patient populations SAN FRANCISCO, May 22, 2023 (GLOBE NEWSWIRE) — Rhythm Technologies, Inc. (NASDAQ:IRTC), a leading digital health care company focused […]
Medtronic Extravascular ICD global clinical trial results reinforce device safety and effectiveness
Late-breaking data at Heart Rhythm 2023 underscore performance of first-of-its-kind investigational defibrillator with the lead placed under the breastbone, outside the heart and veins Additionally, real-world analysis confirms long-term therapeutic benefit of commercially available ICDs DUBLIN and NEW ORLEANS, May 20, 2023 /PRNewswire/ — Medtronic plc (NYSE: MDT), a global leader in healthcare technology, announced longer-term […]
Data at Heart Rhythm 2023 Highlight Key Boston Scientific Therapies
Additional real-world outcomes further demonstrate safety, efficacy and procedural reproducibility of the FARAPULSE™ Pulsed Field Ablation System* Results from global trial of the POLARx™ Cryoablation System* meet safety and effectiveness endpoints MARLBOROUGH, Mass., May 20, 2023 /PRNewswire/ — Boston Scientific Corporation (NYSE: BSX) today announced data supporting use of the company’s key electrophysiology […]
Philips presents findings from retrospective study at HRS 2023, showing AI model’s potential to predict ventricular tachycardia
On May 19, 2023 at the annual Hearth Rhythm Society congress in New Orleans, Louisiana USA, Philips presented an abstract highlighting recent research demonstrating how AI may be used to help predict life-threatening ventricular arrhythmias. The study, entitled Near-Term Prediction of Life-Threatening Ventricular Arrhythmias using Artificial Intelligence-Enabled Single Lead Ambulatory ECG, […]
New urban health ‘accelerator’ aims to transform cardiovascular population health globally
The CARDIO4Cities Accelerator by Novartis Foundation and IntraHealth International aims to replicate the successful CARDIO4Cities approach in 30 major cities within three years to transform cardiovascular population health and equity globally. Results of initial programs in São Paulo, Dakar and Ulaanbaatar show the cost-effective approach averted up to 13% of strokes and 12% […]
Implicity Study Presented in Late-Breaking Clinical Trial Session at Heart Rhythm 2023
Ground-breaking research is the first to link real-world health outcomes to the quality of remote monitoring and data management. Results show significant disparities in mortality rates depending on the method of remote monitoring used. CAMBRIDGE, Mass., May 22, 2023 /PRNewswire/ — Implicity, a leader in remote patient monitoring and cardiac data management solutions, […]



